Immunotherapy based on bispecific T‐cell engager with <scp>hIgG</scp>1 Fc sequence as a new therapeutic strategy in multiple myeloma

Zou, Jianxuan; Chen, Dan; Zong, Yunhui; Ye, Sisi; Tang, Jessica; Meng, Hua; An, Gangli; Zhang, Xingding; Yang, Lin

doi:10.1111/cas.12631

Cited by 49 publications

(39 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zou et al. found that BiTE‐hIgFc (anti‐CD138‐Scfv‐OKT3‐ScFv‐pFUSE‐hIgFc) binding with T cells and NK cells could achieve potent cytotoxicity against RPMI‐8226 cells and significantly inhibit the growth of tumor in myeloma‐bearing mice . NK cells bearing BiTE‐hIgFc have stronger production of lytic granules and upregulate the expression of activation receptors, which set up a more promising strategy and may provide a new idea for NK cell‐targeted therapy.…”

Section: Novel Nk Cell‐based Immunotherapiesmentioning

confidence: 99%

Natural killer cell immunotherapy against multiple myeloma: Progress and possibilities

Liu

Jin

Sattar

et al. 2018

Journal of Leukocyte Biology

View full text Add to dashboard Cite

Multiple myeloma (MM) is a complex aggressive mature B-cell malignancy. Although with the wide application of chemotherapy drugs, it remains incurable and the vast majority of patients relapse. Natural killer (NK) cells, also known as CD56 CD3 large granular lymphocytes, are cytotoxic innate immune cells against MM without prior sensitization steps. NK cell-based immunotherapy is extensively promising in a wide range of clinical settings. It is worthy of note that some novel drugs such as monoclonal antibodies (mAbs), proteasome inhibitors (PIs), and immunomodulators (IMiDs) directly or indirectly activate NK cells to enhance their antitumor activity, and the combined regimens significantly improve the prognosis of MM patients. In this review, we summarize recent findings that support a role for NK cells in the pathogenesis of MM and outline innovative approaches in the implementation of NK cell-based immunotherapy against MM.

show abstract

Section: Novel Nk Cell‐based Immunotherapiesmentioning

confidence: 99%

Natural killer cell immunotherapy against multiple myeloma: Progress and possibilities

Liu

Jin

Sattar

et al. 2018

Journal of Leukocyte Biology

View full text Add to dashboard Cite

show abstract

“…Other targets addressed with bispecific antibodies include CD38 [98], CD138 [99], CD20 [100], and Wue-1 [101]. …”

Section: T Cells Based Approachesmentioning

confidence: 99%

Immunologic approaches for the treatment of multiple myeloma

Rasche

Weinhold

Morgan

et al. 2017

Cancer Treatment Reviews

View full text Add to dashboard Cite

The FDA approval of two monoclonal antibodies in 2015 has heralded a new era of targeted immunotherapies for multiple myeloma (MM). In this review we discuss the recent approaches using different immunological components to treat MM. In particular, we review current monoclonal antibody based therapies, engineered T- and NK cell products, ‘off-target’ immunomodulation, and strategies utilizing allogeneic cell transplantation in MM. We discuss how an immunologic approach offers promise for the treatment of this genetically heterogeneous disease, and how patients with acquired drug resistance may particularly benefit from these therapies. We also describe some of the limitations of the current strategies and speculate on the future of personalized immunotherapies for MM.

show abstract

“…A combination of anti-CD3 scFv and anti-CD138 scFv with the hIgG1 Fc (hIgFc) sequence was developed to form a novel BiTE with an additional hIgFc (BiTE-hIgFc, STL001) [58]. BiTE-hIgFc (STL001) activated T cells effectively and induced cytotoxicity against multiple myeloma cells in vitro and in vivo [58].…”

Section: Bispecific T Cell Engager (Bite)mentioning

confidence: 99%

“…BiTE-hIgFc (STL001) activated T cells effectively and induced cytotoxicity against multiple myeloma cells in vitro and in vivo [58]. It is also the first BiTE to target CD138, CD3, and FcR, which are expressed on multiple myeloma cells, T cells and NK cells, respectively.…”

Section: Bispecific T Cell Engager (Bite)mentioning

confidence: 99%

Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer

Smits

Coupet

Godbersen

et al. 2016

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Introduction Natural killer (NK) cells are an important component of the innate immune system that play a key role in host immunity against cancer. NK cell recognition and activation is based on cell surface receptors recognizing specific ligands that are expressed on many types of tumor cells. Some of these receptors are capable of activating NK cell function while other receptors inhibit NK cell function. Therapeutic approaches to treat cancer have been developed based on preventing NK cell inhibition or using NK cell receptors and their ligands to activate NK cells or T cells to destroy tumor cells. Areas covered This article describes the various strategies for targeting NK cell receptors and NK cell receptor ligands using multivalent proteins to activate immunity against cancer. Expert opinion: NK cell receptors work in synergy to activate NK cell effector responses. Effective anti-cancer strategies will need to not only kill tumor cells but must also lead to the destruction of the tumor microenvironment. Immunotherapy based on NK cells and their receptors has the capacity to accomplish this through triggering lymphocyte cytotoxicity and cytokine production.

show abstract

Immunotherapy based on bispecific T‐cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma

Cited by 49 publications

References 21 publications

Natural killer cell immunotherapy against multiple myeloma: Progress and possibilities

Natural killer cell immunotherapy against multiple myeloma: Progress and possibilities

Immunologic approaches for the treatment of multiple myeloma

Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer

Contact Info

Product

Resources

About